Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
Noosa News23 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
Noosa News13 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General8 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
General9 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for